Marcus benefits from premiumization strategies, outperforming industry averages in both box office and hotel RevPAR. Read why I reiterate a Buy for MCS stock.
Opinion
Maclean'sOpinion

Scott Feschuk

Scott Feschuk is a columnist for Maclean's and Sportsnet magazines. He writes speeches for business leaders and politicians of varied political stripes.